IONS - Ionis Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
68.76
-1.68 (-2.39%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close70.44
Open70.32
Bid68.78 x 800
Ask68.79 x 900
Day's Range68.30 - 70.38
52 Week Range41.25 - 86.58
Volume1,132,415
Avg. Volume1,332,785
Market Cap9.649B
Beta (3Y Monthly)1.71
PE Ratio (TTM)25.91
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • Biogen Announces New Data Further Establishing SPINRAZA® (nusinersen) as a Foundation of Care in Spinal Muscular Atrophy for a Broad Range of Patients
    PR Newswire19 days ago

    Biogen Announces New Data Further Establishing SPINRAZA® (nusinersen) as a Foundation of Care in Spinal Muscular Atrophy for a Broad Range of Patients

    - New results from the NURTURE study demonstrate that pre-symptomatic infants treated with SPINRAZA are achieving motor milestones that are unprecedented in the natural history of the disease, including ...

  • GlobeNewswire21 days ago

    Biogen announces European label update for SPINRAZA (nusinersen) which includes longer-term data across a broad range of ages and types of Spinal Muscular Atrophy

    Biogen (BIIB) today announced an update to the European label for nusinersen, incorporating longer-term data from four studies (NURTURE, EMBRACE, SHINE and CS3A). No new safety concerns were identified.

  • GlobeNewswirelast month

    Akcea and Ionis Announce Upcoming Data Presentations at the 2019 Peripheral Nerve Society Annual Meeting

    BOSTON and CARLSBAD, Calif., June 20, 2019 -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ:.

  • Ionis Pharmaceuticals to present at the BMO Prescription for Success Healthcare Conference
    PR Newswirelast month

    Ionis Pharmaceuticals to present at the BMO Prescription for Success Healthcare Conference

    CARLSBAD, Calif., June 18, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (IONS), the leader in antisense therapeutics, today announced that management will present a company overview at the BMO Prescription for Success Healthcare Conference at 9:20 a.m. ET on Tuesday, June 25, 2019 in New York, NY. As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, drug discovery platform called antisense technology that can treat diseases where no other therapeutic approaches have proven effective.

  • Ionis announces appointment of Joan E. Herman to its board of directors
    PR Newswirelast month

    Ionis announces appointment of Joan E. Herman to its board of directors

    CARLSBAD, Calif., June 12, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (IONS), the leader in RNA-targeted therapeutics, today announced the appointment of a new member to its board of directors effective immediately – Joan E. Herman, MBA, MS, president and chief executive officer of Herman and Associates, LLC. With the appointment of Ms. Herman, the Ionis board of directors increases to 12 members. "We are pleased to welcome Joan Herman to the Ionis board.

  • Ionis Pharmaceuticals to provide corporate update and 30-year retrospective at its 2019 Annual Meeting of Stockholders
    PR Newswirelast month

    Ionis Pharmaceuticals to provide corporate update and 30-year retrospective at its 2019 Annual Meeting of Stockholders

    CARLSBAD, Calif., June 6, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (IONS) today announced that Stanley T. Crook, M.D., Ph.D., chairman of the board and chief executive officer, will present a general corporate update and 30-year retrospective in conjunction with its 2019 Annual Meeting of Stockholders and Open House on Thursday, June 6 at 2:10 p.m. Pacific Time (5:10 p.m. Eastern Time) in Carlsbad, CA.

  • GlobeNewswire2 months ago

    Akcea Therapeutics to Present at Upcoming Investor Conferences

    Akcea Therapeutics, Inc., an affiliate of Ionis Pharmaceuticals, Inc. (IONS), is a biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious and rare diseases.

  • GlobeNewswire2 months ago

    Biogen’s SPINRAZA® (nusinersen) Receives Positive Recommendation from NICE for Funding in the United Kingdom for the Treatment of Infants, Children and Adults with Spinal Muscular Atrophy

    Biogen Inc. (BIIB) today announced that The National Institute for Health and Care Excellence (NICE) in the United Kingdom has recommended funding for SPINRAZA (nusinersen) on the National Health Service (NHS). The positive recommendation is for the treatment of infants, children and adults with 5q spinal muscular atrophy (SMA), including pre-symptomatic and symptomatic SMA Types 1, 2 and 3.

  • Ionis reports first quarter 2019 financial results
    PR Newswire2 months ago

    Ionis reports first quarter 2019 financial results

    Revenues more than doubled compared to 2018, resulting in net income of $84 million Nearly $300 million in revenues driven by $150 million license fee from Novartis and growing commercial revenues Conference ...

  • GlobeNewswire2 months ago

    Akcea Reports Financial Results and Highlights for First Quarter 2019

    Achieved First Quarter 2019 TEGSEDI® (inotersen) Global Net Product Revenues of $7 Million  Novartis exercised its option to license AKCEA-APO(a)-LRx Received marketing.

  • GlobeNewswire2 months ago

    New Long-Term TEGSEDI Safety and Efficacy Data Featured as an Oral Presentation at 2019 American Academy of Neurology Annual Meeting (AAN)

    Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (IONS) today announced new long-term, open-label extension (OLE) data from the NEURO-TTR study of TEGSEDI® (inotersen) in patients with hereditary ATTR amyloidosis (hATTR) with polyneuropathy. The data was highlighted as an oral presentation at the 2019 American Academy of Neurology (AAN) Annual Meeting in Philadelphia.

  • GlobeNewswire2 months ago

    Akcea and Ionis Announce Approval of WAYLIVRA® (volanesorsen) in the European Union

    Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (IONS), announced today that WAYLIVRA has received conditional marketing authorization from the European Commission (EC) as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk for pancreatitis, in whom response to diet and triglyceride lowering therapy has been inadequate. This authorization follows the positive opinion recommending approval provided by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).

  • Ionis launches new corporate brand that reflects company's industry-leading innovation and unique culture of saying "yes" to patients
    PR Newswire2 months ago

    Ionis launches new corporate brand that reflects company's industry-leading innovation and unique culture of saying "yes" to patients

    CARLSBAD, Calif., May 6, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (IONS) today unveiled its new corporate brand in a campaign inspired by its unique culture and history of developing transformative therapies for seemingly untreatable diseases. The brand refresh comes as Ionis celebrates its 30th anniversary. "Our new brand is a bold, fresh expression of what we've lived and breathed at Ionis for 30 years – an unwavering passion for discovering and developing novel medicines and a steadfast commitment to saying yes to the patients who depend on us to create them," said Stanley T. Crooke, M.D., Ph.D., Ionis' founder, chairman and chief executive officer.

  • GlobeNewswire3 months ago

    Akcea Announces Upcoming Data Presentations at the 2019 American Academy of Neurology Meeting (AAN.19)

    Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc. (IONS), today announced that data from the NEURO-TTR open-label extension study and the clinical impact of TEGSEDI on patients living with hereditary transthyretin amyloidosis (hATTR) will be presented at the American Academy of Neurology 71st Annual Meeting (AAN) in Philadelphia, May 4-10, 2019.

  • PR Newswire3 months ago

    Positive clinical data at AAN 2019 reinforces Ionis' commitment to delivering life-changing medicines to patients with neurological diseases

    Twelve presentations highlighting transformational medicines for SMA, hATTR, Huntington's disease, ALS, prion disease and others Updates on RG6042 (IONIS-HTTRx) and tofersen (IONIS-SOD1Rx), two of at least ...

  • PR Newswire3 months ago

    Ionis Pharmaceuticals to hold first quarter 2019 financial results webcast

    CARLSBAD, Calif., April 25, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (IONS) announced today that it will host a live webcast on Thursday, May 9th at 11:30 a.m. Eastern Time to discuss its first quarter 2019 financial results and report on pipeline and business progress. As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, drug discovery platform called antisense technology that can treat diseases where no other therapeutic approaches have proven effective.

  • GlobeNewswire3 months ago

    Akcea Therapeutics to Hold First Quarter 2019 Financial Results Webcast

    Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc., announced today that it will host a live webcast on Wednesday, May 8th at 4:30 p.m. Eastern Time to discuss its first quarter 2019 financial results and report on pipeline and business progress. Akcea Therapeutics, Inc., an affiliate of Ionis Pharmaceuticals, Inc. (IONS), is a biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious and rare diseases. All six drugs were discovered by and are being co-developed with Ionis, a leader in antisense therapeutics, and are based on Ionis’ proprietary antisense technology.

  • PR Newswire3 months ago

    Ionis Pharmaceuticals to Provide Corporate Update at 2019 Annual Meeting of Stockholders

    CARLSBAD, Calif., April 8, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (IONS) today announced that management will present a general corporate update in conjunction with its 2019 Annual Meeting of Stockholders and Open House on Thursday, June 6 at 2:10 p.m. Pacific Time (5:10 p.m. Eastern Time) in Carlsbad, CA.

  • PR Newswire4 months ago

    Ionis announces appointment of Brett P. Monia Ph.D. to its board of directors

    CARLSBAD, Calif., March 25, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (IONS), the leader in RNA-targeted therapeutics, today announced that Brett P. Monia, Ph.D., has been appointed to the company's board of directors. Dr. Monia currently serves as Ionis' chief operating officer and, as was previously announced, will be appointed chief executive officer of the company in January 2020, succeeding current CEO Stanley T. Crooke, M.D., Ph.D., who will become executive chairman of the Ionis board of directors. With the addition of Dr. Monia, the Ionis board now has a total of 11 members.

  • GlobeNewswire4 months ago

    Akcea and Ionis Announce Upcoming Data Presentations at the 2019 American College of Cardiology Meeting (ACC.19)

    Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (IONS) today announced that data from the NEURO-TTR open-label extension study and the clinical impact of TEGSEDI on patients living with hereditary transthyretin amyloidosis (hATTR) will be presented at the American College of Cardiology’s 68th Annual Scientific Session (ACC) in New Orleans, March 16-18, 2019.

  • PR Newswire4 months ago

    Ionis Pharmaceuticals to Present at Upcoming Investor Conferences

    As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, drug discovery platform called antisense technology that can treat diseases where no other therapeutic approaches have proven effective. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement.

  • GlobeNewswire5 months ago

    Detailed Research: Economic Perspectives on Huntsman, eHealth, Ionis Pharmaceuticals, Arch Capital Group, Copart, and Acorda Therapeutics — What Drives Growth in Today's Competitive Landscape

    NEW YORK, March 04, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • GlobeNewswire5 months ago

    Akcea and Ionis Receive Positive EU CHMP Opinion for WAYLIVRATM (volanesorsen)

    Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (IONS), announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending conditional marketing authorization for WAYLIVRA as an adjunct to diet in adult patients with genetically confirmed familial chylomicronemia syndrome (FCS) who are at high risk for pancreatitis, in whom response to diet and triglyceride lowering therapy has been inadequate. Click here to read the EMA’s press release. The positive opinion will now be referred to the European Commission (EC), which grants marketing authorization for medicines in the European Union for the adoption of a decision on an EU-wide marketing authorization.

  • PR Newswire5 months ago

    Ionis Exceeds 2018 Financial Guidance

    Total revenue increased 17% compared to 2017 to $600 million Commercial revenues more than doubled Conference call and webcast today, February 27, 2019, at 11:30 a.m. Eastern Time CARLSBAD, Calif. , Feb. ...